Profound Medical CFO Steps Down

TORONTO, Nov. 17, 2015 (GLOBE NEWSWIRE) -- Profound Medical Corp. ("Profound" or the "Company") (PRN.V) today announced that Mr. Shameze Rampertab has tendered his resignation as Chief Financial Officer of the Company. Mr. Rashed Dewan, the Company's Corporate Controller, will assume Mr. Rampertab's responsibilities as the Company's interim Chief Financial Officer ("CFO"). The Company intends to commence a search for a new CFO in due course.

Steven Plymale, Chief Executive Officer of the Company commented, "On behalf of the management team and Board of Directors, I would like to thank Shameze for his contributions to Profound Medical. He played a critical role in our recently completed going public transaction and the Board and I wish him success in his future endeavors."

About Profound Medical Corp.

Profound is a Canadian medical device company that has developed a unique and minimally invasive treatment to ablate the prostate gland in prostate cancer patients. Profound's novel technology combines real-time MR imaging with transurethral therapeutic ultrasound and closed-loop thermal feedback control. It provides a highly precise treatment tailored to patient-specific anatomy and pathology. This method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery. The potential of this technology is currently being demonstrated in clinical trials. For more information, visit

Notice regarding forward-looking statements:

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound's technology in the treatment of prostate cancer. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For investor or media inquiries, please contact:
Steven Plymale
Profound Medical Corp.
[email protected]
T: 647-476-1350, Ext. 401
Rebecca von Goetz
Senior Marketing & Communications Specialist
Profound Medical Corp.
[email protected]
T: 647-476-1350, Ext. 426
C: 416.917.8650

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.